An updated patent review

xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015)

Ritu Ojha, Jagjeet Singh, Anu Ojha, Harbinder Singh, Sahil Sharma, Kunal Nepali

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Introduction: Xanthine oxidase (XO) is a versatile molybdoflavoprotein, widely distributed, occurring in milk, kidney, lung, heart, and vascular endothelium. Catalysis by XO to produce uric acid and reactive oxygen species leads to many diseases. Anti hyperuricemic therapy by xanthine oxidase inhibitors has been mainly employed for the treatment of gout. Area covered: This review covers the patent literature (2011–2015) and also presents the interesting strategies/rational approaches employed for the design of xanthine oxidase inhibitors reported recently. Expert opinion: Recent literature indicates that various non purine scaffolds have been extensively investigated for xanthine oxidase inhibition. The significant potential endowed by heteroaryl based compounds, in particularly fused heterocycles clearly highlights their clinical promise and the need for detailed investigation. Studies by various research groups have also revealed that the flavone framework is open for isosteric replacements and structural modifications for yielding potent non purine xanthine oxidase inhibitors. In addition, various plant extracts recently reported to possess significant xanthine oxidase inhibitory potential presents enough promise to initiate a screening program for the identification of other plant extracts and phytoconstituents possessing inhibitory potential towards the enzyme.

Original languageEnglish
Pages (from-to)311-345
Number of pages35
JournalExpert Opinion on Therapeutic Patents
Volume27
Issue number3
DOIs
Publication statusPublished - Mar 4 2017
Externally publishedYes

Fingerprint

Hyperuricemia
Xanthine Oxidase
Gout
flavone
Plant Extracts
Literature
Patents
Vascular Endothelium
Expert Testimony
Uric Acid
Catalysis
Reactive Oxygen Species
Milk
Kidney
Lung
Enzymes
Research

Keywords

  • allopurinol
  • febuxostat
  • gout
  • non purine
  • purine
  • Xanthine oxidase inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

An updated patent review : xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015). / Ojha, Ritu; Singh, Jagjeet; Ojha, Anu; Singh, Harbinder; Sharma, Sahil; Nepali, Kunal.

In: Expert Opinion on Therapeutic Patents, Vol. 27, No. 3, 04.03.2017, p. 311-345.

Research output: Contribution to journalReview article

Ojha, Ritu ; Singh, Jagjeet ; Ojha, Anu ; Singh, Harbinder ; Sharma, Sahil ; Nepali, Kunal. / An updated patent review : xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015). In: Expert Opinion on Therapeutic Patents. 2017 ; Vol. 27, No. 3. pp. 311-345.
@article{eff3fde6bd6b41379dd29319b61daab3,
title = "An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015)",
abstract = "Introduction: Xanthine oxidase (XO) is a versatile molybdoflavoprotein, widely distributed, occurring in milk, kidney, lung, heart, and vascular endothelium. Catalysis by XO to produce uric acid and reactive oxygen species leads to many diseases. Anti hyperuricemic therapy by xanthine oxidase inhibitors has been mainly employed for the treatment of gout. Area covered: This review covers the patent literature (2011–2015) and also presents the interesting strategies/rational approaches employed for the design of xanthine oxidase inhibitors reported recently. Expert opinion: Recent literature indicates that various non purine scaffolds have been extensively investigated for xanthine oxidase inhibition. The significant potential endowed by heteroaryl based compounds, in particularly fused heterocycles clearly highlights their clinical promise and the need for detailed investigation. Studies by various research groups have also revealed that the flavone framework is open for isosteric replacements and structural modifications for yielding potent non purine xanthine oxidase inhibitors. In addition, various plant extracts recently reported to possess significant xanthine oxidase inhibitory potential presents enough promise to initiate a screening program for the identification of other plant extracts and phytoconstituents possessing inhibitory potential towards the enzyme.",
keywords = "allopurinol, febuxostat, gout, non purine, purine, Xanthine oxidase inhibitors",
author = "Ritu Ojha and Jagjeet Singh and Anu Ojha and Harbinder Singh and Sahil Sharma and Kunal Nepali",
year = "2017",
month = "3",
day = "4",
doi = "10.1080/13543776.2017.1261111",
language = "English",
volume = "27",
pages = "311--345",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - An updated patent review

T2 - xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015)

AU - Ojha, Ritu

AU - Singh, Jagjeet

AU - Ojha, Anu

AU - Singh, Harbinder

AU - Sharma, Sahil

AU - Nepali, Kunal

PY - 2017/3/4

Y1 - 2017/3/4

N2 - Introduction: Xanthine oxidase (XO) is a versatile molybdoflavoprotein, widely distributed, occurring in milk, kidney, lung, heart, and vascular endothelium. Catalysis by XO to produce uric acid and reactive oxygen species leads to many diseases. Anti hyperuricemic therapy by xanthine oxidase inhibitors has been mainly employed for the treatment of gout. Area covered: This review covers the patent literature (2011–2015) and also presents the interesting strategies/rational approaches employed for the design of xanthine oxidase inhibitors reported recently. Expert opinion: Recent literature indicates that various non purine scaffolds have been extensively investigated for xanthine oxidase inhibition. The significant potential endowed by heteroaryl based compounds, in particularly fused heterocycles clearly highlights their clinical promise and the need for detailed investigation. Studies by various research groups have also revealed that the flavone framework is open for isosteric replacements and structural modifications for yielding potent non purine xanthine oxidase inhibitors. In addition, various plant extracts recently reported to possess significant xanthine oxidase inhibitory potential presents enough promise to initiate a screening program for the identification of other plant extracts and phytoconstituents possessing inhibitory potential towards the enzyme.

AB - Introduction: Xanthine oxidase (XO) is a versatile molybdoflavoprotein, widely distributed, occurring in milk, kidney, lung, heart, and vascular endothelium. Catalysis by XO to produce uric acid and reactive oxygen species leads to many diseases. Anti hyperuricemic therapy by xanthine oxidase inhibitors has been mainly employed for the treatment of gout. Area covered: This review covers the patent literature (2011–2015) and also presents the interesting strategies/rational approaches employed for the design of xanthine oxidase inhibitors reported recently. Expert opinion: Recent literature indicates that various non purine scaffolds have been extensively investigated for xanthine oxidase inhibition. The significant potential endowed by heteroaryl based compounds, in particularly fused heterocycles clearly highlights their clinical promise and the need for detailed investigation. Studies by various research groups have also revealed that the flavone framework is open for isosteric replacements and structural modifications for yielding potent non purine xanthine oxidase inhibitors. In addition, various plant extracts recently reported to possess significant xanthine oxidase inhibitory potential presents enough promise to initiate a screening program for the identification of other plant extracts and phytoconstituents possessing inhibitory potential towards the enzyme.

KW - allopurinol

KW - febuxostat

KW - gout

KW - non purine

KW - purine

KW - Xanthine oxidase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85011965787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011965787&partnerID=8YFLogxK

U2 - 10.1080/13543776.2017.1261111

DO - 10.1080/13543776.2017.1261111

M3 - Review article

VL - 27

SP - 311

EP - 345

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 3

ER -